Cephalon’s Nuvigil sNDA Granted FDA Priority Review Status

Drug Industry Daily
A A
Cephalon’s sNDA for Nuvigil to improve wakefulness in patients with jet lag has received priority review status from the FDA.

To View This Article:

Login

Subscribe To Drug Industry Daily